Get the Stockscreener App
57.06
3.91%
-2.32
After Hours:
57.06
Nektar Therapeutics stock is traded at $57.06, with a volume of 2.53M.
It is down -3.91% in the last 24 hours and down -23.88% over the past month.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
See More
Previous Close:
$59.38
Open:
$59.77
24h Volume:
2.53M
Relative Volume:
2.68
Market Cap:
$1.95B
Revenue:
$55.63M
Net Income/Loss:
$-158.10M
P/E Ratio:
-6.7766
EPS:
-8.4202
Net Cash Flow:
$-203.94M
1W Performance:
-14.96%
1M Performance:
-23.88%
6M Performance:
-20.84%
1Y Performance:
+2.59%
1-Day Range:
$57.04
$60.98
1-Week Range:
$56.21
$69.84
52-Week Range:
$33.40
$109.00
Nektar Therapeutics Stock (NKTR) Company Profile
Name
Nektar Therapeutics
Sector
Industry
Phone
(415) 482-5300
Address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
57.06 | 1.95B | 55.63M | -158.10M | -203.94M | -8.4202 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Initiated | Wedbush | Neutral |
| Mar-17-26 | Initiated | TD Cowen | Buy |
| Feb-10-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-26-25 | Initiated | Citigroup | Buy |
| Jun-24-25 | Reiterated | BTIG Research | Buy |
| Jun-24-25 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-14-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-08-25 | Initiated | B. Riley Securities | Buy |
| Dec-10-24 | Initiated | H.C. Wainwright | Buy |
| Nov-04-24 | Initiated | Piper Sandler | Overweight |
| Sep-30-24 | Resumed | BTIG Research | Buy |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Nov-09-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| May-10-23 | Upgrade | Jefferies | Underperform → Hold |
| Feb-24-23 | Downgrade | Jefferies | Hold → Underperform |
| Aug-08-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-31-22 | Resumed | Jefferies | Hold |
| Apr-18-22 | Downgrade | Goldman | Neutral → Sell |
| Mar-15-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-15-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-14-22 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-14-22 | Downgrade | Stifel | Buy → Hold |
| Mar-14-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-09-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-08-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Sep-10-21 | Initiated | BofA Securities | Neutral |
| Jun-28-21 | Upgrade | Stifel | Hold → Buy |
| May-18-21 | Resumed | Goldman | Neutral |
| Feb-22-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jan-06-21 | Initiated | Stifel | Hold |
| Sep-14-20 | Initiated | JP Morgan | Neutral |
| Jun-10-20 | Downgrade | CFRA | Hold → Sell |
| May-12-20 | Reiterated | H.C. Wainwright | Neutral |
| Apr-22-20 | Initiated | The Benchmark Company | Buy |
| Mar-30-20 | Upgrade | Goldman | Sell → Neutral |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-03-20 | Upgrade | Mizuho | Neutral → Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-08-19 | Downgrade | Goldman | Buy → Sell |
| Aug-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-09-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-09-19 | Downgrade | Mizuho | Buy → Neutral |
| Mar-15-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-13-18 | Initiated | Goldman | Buy |
| Jun-11-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-04-18 | Reiterated | H.C. Wainwright | Buy |
| Apr-20-18 | Initiated | Seaport Global Securities | Buy |
| Apr-13-18 | Resumed | Piper Jaffray | Overweight |
| Apr-06-18 | Reiterated | Mizuho | Buy |
| Apr-02-18 | Resumed | H.C. Wainwright | Buy |
View All
Nektar Therapeutics Stock (NKTR) Latest News
Nektar Therapeutics Director Roy Whitfield Reports Acquisition of RSUs and Stock Options - Kalkine Media
Form 4 Nektar Therapeutics For: 25 September By Investing.com - Investing.com Nigeria
Nektar Therapeutics (NKTR) grants a director 2,000 shares upon vesting and options to buy 4,000 more. - Stock Titan
A director receives 2,000 stock units alongside 4,000 options at Nektar Therapeutics (NKTR). - Stock Titan
Director Robert Chess also received 2,000 stock units from Nektar Therapeutics (NKTR), vesting in one year. - Stock Titan
Director Diana Brainard receives 2,000 stock units from Nektar Therapeutics (NKTR), vesting in one year. - Stock Titan
Nektar Therapeutics awarded $90 million in jury verdict against Eli Lilly By Investing.com - Investing.com South Africa
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - prnewswire.com
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says - Reuters
Microsoft, Nike, Nektar Therapeutics - TradingView
Nektar Therapeutics Wins $90M Lilly Verdict - grafa.com
Nektar Therapeutics stock rises on $90M jury verdict vs Lilly - Investing.com
Lilly ordered to pay Nektar $90M in damages over rezpeg dispute - FirstWord
Jury awards Nektar Therapeutics $90M in rezpeg dispute with Eli Lilly - Dealroom
Nektar prevails in legal battle with Lilly over broken rezpeg partnership - BioSpace
Update: Nektar Wins $90 Million Jury Verdict Against Eli Lilly Over Rezpegaldesleukin Deal - Yahoo Finance
Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury FundsEli Lilly (NYS - Benzinga
BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target - TradingView
Nektar Gets $90 Million Jury Award in Breach Suit Against Eli Lilly — Update - Morningstar
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data - Yahoo Finance
Why is Nektar Therapeutics stock climbing today? - Investing.com
Form 8K Nektar Therapeutics For: 25 September By Investing.com - Investing.com India
Nektar Therapeutics awarded $90 million in jury verdict against Eli Lilly - Investing.com Canada
Nektar gains 5% as jury awards $90M plus interest in Lilly trial - TradingView
Nektar Therapeutics awarded $90M jury verdict against Eli Lilly over rezpegaldesleukin dispute - TradingView
Nektar TherapeuticsJury Finds Lilly Breached Implied Covenant Of Good Faith In License Agreement - TradingView
Eli Lilly Hit With $90M Verdict In Nektar's Rezpeg Breach Suit - law360.com
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Nektar Therapeutics stock gains 2.98 percent on trial watch - AD HOC NEWS
Wedbush maintains Neutral rating on Nektar Therapeutics, $50 price target - TradingView
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits
Nektar Therapeutics stock falls 9.6 percent as patent case weighs - AD HOC NEWS
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Nektar Therapeutics drops as jury deliberates in Eli Lilly dispute over Rezpeg - TradingView
How Investors Are Reacting To Nektar Therapeutics (NKTR) Index Reclassification - simplywall.st
Nektar Therapeutics(NasdaqCM: NKTR) added to S&P Biotechnology Select Industry Index - marketscreener.com
Nektar Therapeutics(NasdaqCM:NKTR) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
Nektar Therapeutics (NKTR), What Is Drawing Fresh Attention Now? - simplywall.st
Lilly Left Nektar Drug 'Damaged Goods,' Jury Told At Trial End - law360.com
Nektar Therapeutics stock gains after Q2 loss narrows - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Investors to Connect - ACCESS Newswire
Nektar Therapeutics options flow shows bullish bets against a bearish tape - Investing.com
Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates - Eastern Progress
Lilly Owes Nektar $1B If It Breached Rezpeg Deal, Jury Told - Law360
Nektar CEO Opens Door To Finance Questions In Eli Lilly Trial - Law360
Nektar to Release 24-Week Off-Treatment Data for Rezpegaldesleukin in Alopecia Areata - The Clinical Trial Vanguard
Eli Lilly 'Sabotaged' Rezpeg's Development, Nektar Tells Jury - Law360
Lancet Phase 2b REZOLVE-AD Data Could Be A Game Changer For Nektar Therapeutics (NKTR) - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect - ACCESS Newswire
Nektar Therapeutics (NKTR) Lands Lancet Backing, Is The Upside Already Priced In? - simplywall.st
2026-09-06 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect | NDAQ:NKTR | Press Release - stockhouse.com
Nektar Therapeutics Stock (NKTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):